The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

VHIO’s novel CAR T-cell therapy demonstrates efficacy and safety in preclinical models of HER2-positive solid tumors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

One-third of HER2-positive tumors express the P95HER2 protein, which associates with an aggressive form of breast cancer with a poorer prognosis. Investigators of the Vall d’Hebron Institute of Oncology’s Growth Factors Group, in collaboration with researchers of the Cancer Research Program of Hospital del Mar Research Institute, Barcelona, have developed novel chimeric antigen receptor T-cell therapy that can produce a potent antitumor response against p95HER2-expressing cells.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

As the chief scientific officer of the Leukemia & Lymphoma Society for the past eleven years, it has been a privilege to lead a group of scientists that has doled out more than $600 million for cutting-edge hematologic oncology research. These dollars went to more than 1,000 research projects through initiatives like our biomedical research grant programs and LLS’s venture philanthropy, the Therapy Acceleration Program (TAP). 
By Lee Greenberger
Sponsored

Less taxing therapies taking center stage

Advances such as new nontoxic, more effective immunotherapy and improvements that significantly reduce recovery times for complicated surgeries are making cancer treatments less taxing. On the horizon are more ways to give patients the greatest chance of survival while also reducing negative consequences of treatment. Some therapies also will improve the experience, such as chemotherapy consisting of quick subcutaneous injections instead of hours in an infusion chair. 
By City of Hope
Clinical Roundup

In HER2+ CRC, anti-HER2 therapy may be less toxic alternative to EGFR inhibitors, phase II study finds

A phase II trial found that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy. Exploratory analysis suggests greater HER2 amplification in a tumor may be associated with greater clinical benefit of dual HER2 inhibitor vs EGFR inhibitor therapy.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account